Dr. Kirsh on Advancements in Diagnosing Prostate Cancer

Gary Kirsh, MD
Published: Thursday, May 04, 2017



Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses advancements in diagnosing patients with prostate cancer.

In terms of diagnosing prostate cancer, it has become easier to determine who needs an invasive procedure such as a prostate biopsy, explains Kirsh. For example, there are tests, such as PCA3, 4Kscore, and Prostate Health Index score, used to better determine whether an elevated prostate-specific antigen is meaningful before you do a biopsy.

By utilizing these advancements, the aim is to avoid invasive prostate biopsies if possible, states Kirsh. Furthermore, by improving the accuracy of the biopsies, such as with MRI fusion technology, a patient does not need to endure multiple biopsies.


Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses advancements in diagnosing patients with prostate cancer.

In terms of diagnosing prostate cancer, it has become easier to determine who needs an invasive procedure such as a prostate biopsy, explains Kirsh. For example, there are tests, such as PCA3, 4Kscore, and Prostate Health Index score, used to better determine whether an elevated prostate-specific antigen is meaningful before you do a biopsy.

By utilizing these advancements, the aim is to avoid invasive prostate biopsies if possible, states Kirsh. Furthermore, by improving the accuracy of the biopsies, such as with MRI fusion technology, a patient does not need to endure multiple biopsies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x